MEBGEN™ BRAF Kit Receives MHLW Approval as Companion Diagnostic for Use with Patients with Melanoma

On August 1, 2022 Medical and Biological Laboratories Co., Ltd. ("MBL"), a JSR Life Sciences Company, reported that MEBGEN BRAF Kit, an in vitro diagnostic reagent, was approved for detection of BRAF gene mutations (V600E or V600K) by the Ministry of Health, Labour and Welfare (MHLW) for production and marketing in Japan on July 7, 2022 (Press release, JSR, AUG 1, 2022, View Source [SID1234617164]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MEBGEN BRAF Kit was developed as a companion diagnostic for multiple anti-cancer agents in melanoma. The MEBGEN BRAF Kit is expected to be an important clinical diagnostic in guiding personalized medicine for patients with melanoma.

G1 Therapeutics to Participate Virtually in the 2022 BTIG Biotechnology Conference and the 2022 Wedbush Pacgrow Healthcare Conference

On August 1, 2022 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that the Company will participate in two upcoming virtual investor conferences in August 2022 (Press release, G1 Therapeutics, AUG 1, 2022, View Source [SID1234617163]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Tuesday August 9, 2022, G1’s Chief Executive Officer Jack Bailey and other members of the executive team will participate in the virtual 2022 BTIG Biotechnology Conference. BTIG-hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest.

On Wednesday August 10, 2022, Jack Bailey and other members of the executive team will participate in the virtual 2022 Wedbush Pacgrow Healthcare Conference. Mr. Bailey will participate in a "Commercial Oncology" panel at 8:35AM ET. The webcast and replay of this event will be accessible on the Events & Presentations page of View Source